A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma - Concepedia

Concepedia

Publication | Open Access

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

DOI Full Paper Access

115

Citations

16

References

2022

Year

Anita D’Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Katja Weisel, Orlando F. Bueno, Rajvineeth Kumar Pothacamury, Kevin J. Freise, Susan Yue, Jeremy A. Ross,

Journal of Clinical Oncology

Abstract

ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.

References

	Year	Citations

Page 1